PL EN


Preferences help
enabled [disable] Abstract
Number of results
2012 | 59 | 4 | 561-566
Article title

High mobility group B1 levels in sepsis and disseminated intravascular coagulation

Content
Title variants
Languages of publication
EN
Abstracts
EN
Cytokines trigger coagulant and fibrinolytic systems in sepsis to result in Disseminated Intravascular Coagulation (DIC) that is an important complication and leads to disseminated hemorrhages and multi-organ failure. High Mobility Group B1 DNA Binding (HMGB1) protein is a cytokine taking part in systemic inflammatory response. The objective of this study was to investigate HMGB1 levels in groups of septic patients with and without DIC.Twenty-one septic patients without DIC and 12 septic patients with DIC from the Intensive Care Unit (ICU) were included in the study. In addition, 20 patients admitted to the ICU without sepsis or DIC and 20 healthy volunteers served as controls. Levels of HMGB1, prothrombin time, activated partial thromboplastin time, fibrinogen, D-dimer, protein C, protein S, anti-thrombin III (ATIII), platelet (thrombocyte) and leukocyte count were determined. Levels of fibrinogen, protein C, ATIII and platelet count were significantly lower and D-dimer was significantly higher in the group with sepsis plus DIC compared to the group with sepsis without DIC. Levels of HMGB1 were higher in the group with sepsis and DIC compared to the group with sepsis; however, the difference was not statistically significant and the levels of HGMB1 of both groups were significantly higher compared to ICU and healthy control groups. HMGB1 levels were not significantly different in survivor and non survivor patients. HMGB1 levels did not differ in lower respiratory tract infection (LRTI) and urinary tract infection (UTI) in regard to the etiology of sepsis.
Publisher

Year
Volume
59
Issue
4
Pages
561-566
Physical description
Dates
published
2012
received
2012-01-08
revised
2012-09-21
accepted
2012-10-15
(unknown)
2012-10-23
Contributors
  • Department of Biochemistry, Zonguldak Karaelmas University, Faculty of Medicine, Esenköy-Kozlu-Zonguldak, Turkey
  • Department of Biochemistry, Zonguldak Karaelmas University, Faculty of Medicine, Esenköy-Kozlu-Zonguldak, Turkey
author
  • Department of Infectious Diseases, Zonguldak Karaelmas University, Faculty of Medicine, Esenköy-Kozlu-Zonguldak, Turkey
  • Department of Biochemistry, Zonguldak Karaelmas University, Faculty of Medicine, Esenköy-Kozlu-Zonguldak, Turkey
author
  • Department of Biochemistry, Zonguldak Karaelmas University, Faculty of Medicine, Esenköy-Kozlu-Zonguldak, Turkey
author
  • Department of Biochemistry, Zonguldak Karaelmas University, Faculty of Medicine, Esenköy-Kozlu-Zonguldak, Turkey
  • Department of Biostatistics, Zonguldak Karaelmas University, Faculty of Medicine, Esenköy-Kozlu-Zonguldak, Turkey
References
  • Bochud PY, Calandra T (2003) Pathogenesis of sepsis: new concepts and implications for future treatment. BMJ 326: 262-266.
  • Bone RC, Balk RA, Cerra FB, Dellinger RP, Fein AM, Knaus WA, Schein RM, Sibbald WJ (1992) ACCP/SCCM Consensus Conference: Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Chest 101: 1644-1655.
  • Cinel I, Opal SM (2009) Molecular biology of inflammation and sepsis: a primer. Crit Care Med 37: 291-304.
  • Cohen J (2002) The immunopathogenesis of sepsis. Nature 420: 885-891.
  • Flohr AM, Rogalla P, Meiboom M, Borrmann L, Krohn M, Thode-Halle B, Bullerdiek J (2001) Variation of HMGB1 expression in breast cancer. Anticancer Res 21: 3881-3885.
  • Fourrier F, Chopin C, Goudemand J, Hendrycx S, Caron C, Rime A, Marey A, Lestavel P (1992) Septic shock, multiple organ failure and disseminated intravascular coagulation compared patterns of antithrombin III, protein C and protein S deficiencies. Chest 101: 816-823.
  • Gaini S, Koldkjaer OG, Møller HJ, Pedersen C, Pedersen SS (2007) A comparison of high-mobility group-box 1 protein, lipopolysaccharide-binding protein and procalcitonin in severe community-acquired infections and bacteraemia: a prospective study. Crit Care 11: R76.
  • Gibot S, Massin F, Cravoisy A, Barraud D, Nace L, Levy B, Bollaert PE (2007) High-mobility group box 1 protein plasma concentrations during septic shock. Intensive Care Med 33: 1347-1353.
  • Hatada T, Wada H, Nobori T, Okabayashi K, Maruyama K, Abe Y, Uemoto S, Yamada S, Maruyama I (2005) Plasma concentrations and importance of High Mobility Group Box protein in the prognosis of organ failure in patients with disseminated intravascular coagulation. Thromb Haemost 94: 975-979.
  • Karlsson S, Pettilä V, Tenhunen J, Laru-Sompa R, Hynninen M, Ruokonen E (2008) HMGB1 as a predictor of organ dysfunction and outcome in patients with severe sepsis. Intensive Care Med 34: 1046-1053.
  • Levy MM, Fink MP, Marshall JC, Abraham E, Angus D, Cook D et al. (2003) 2001 SCCM/ESICM/ACCP/ATS/SIS International sepsis definitions conference. Intensive Care Med 29: 530-538.
  • Levi M, Toh CH, Thachil J, Watson HG (2009) Guidelines for the diagnosis and management of disseminated intravascular coagulation. British Committee for Standards in Haematology. Br J Haematol 145: 24-33.
  • Lotze MT, Tracey KJ (2005) High-mobility group box 1 protein (HMGB1): nuclear weapon in the immune arsenal. Nat Rev Immunol 5: 331-342
  • Mujun Y, Nardella A, Pechet L (2000) Screening tests of disseminated intravascular coagulation: Guidelines for rapid and specific laboratory diagnosis. Crit Care Med 28: 1777-1780
  • Peters K, Unger RE, Brunner J, Kirkpatrick CJ (2003) Molecular basis of endothelial dysfunction in sepsis. Cardiovasc Res 60: 49-57.
  • Poser I, Golob M, Buettner R, Bosserhoff AK (2003) Upregulation of HMG1 leads to melanoma inhibitory activity expression in malignant melanoma cells and contributes to their malignancy phenotype. Mol Cell Biol 23: 2991-2998.
  • Shimaoka M, Park EJ. (2008) Advances in understanding sepsis. Eur J Anaesthesiol Suppl 42: 146-53.
  • Sundén-Cullberg J, Norrby-Teglund A, Rouhiainen A, Rauvala H, Herman G, Tracey KJ et al (2005) Persistent elevation of high mobility group box-1 protein (HMGB1) in patients with severe sepsis and septic shock. Crit Care Med 33: 564-573.
  • Taylor FB Jr, Toh CH, Hoots WK, Wada H, Levi M (2001) Towards definition, clinical and laboratory criteria, and a scoring system for disseminated intravascular coagulation. Scientific Subcommittee on Disseminated Intravascular Coagulation (DIC) of the International Society on Thrombosis and Haemostasis (ISTH). Thromb Haemost 86: 1327-1330.
  • Ulloa L, Tracey KJ (2005) The 'cytokine profile': a code for sepsis. Trends Mol Med 11: 56-63.
  • Van Zoelen MA, Laterre PF, Van Veen SQ, Van Till JW, Wittebole X, Bresser P et al (2007) Systemic and local high mobility group box 1 concentrations during severe infection. Crit Care Med 35: 2799-2804.
  • Völp K, Brezniceanu ML, Bösser S, Brabletz T, Kirchner T, Göttel D, Joos S, Zörnig M (2006) Increased expression of high mobility group box 1 (HMGB1) is associated with an elevated level of the antiapoptotic c-IAP2 protein in human colon carcinomas. Gut 55: 234-242.
  • Wang H, Bloom O, Zhang M, Vishnubhakat JM, Ombrellino M, Che J et al (1999) HMG-1 as a late mediator of endotoxin lethality in mice. Science 285: 248-251.
  • Zeerleder S, Hack CE, Wuillemin WA (2005) Disseminated intravascular coagulation in sepsis. Chest 128: 2864-2875.
Document Type
Publication order reference
Identifiers
YADDA identifier
bwmeta1.element.bwnjournal-article-abpv59p561kz
JavaScript is turned off in your web browser. Turn it on to take full advantage of this site, then refresh the page.